#DatopotamabDeruxtecan
LightNews LightNews
oncodaily.bsky.social
A new ADC is now available to treat the most common subtype of breast cancer - Paolo Tarantino
@ptarantinomd.bsky.social
@fda.gov

oncodaily.com/science/paol...

#BreastCancer #Cancer #DatopotamabDeruxtecan #Medicine #OncoDaily #Oncology #TB01trial #Health
Paolo Tarantino: A new ADC is now available to treat the most common subtype of breast cancer - OncoDaily
Paolo Tarantino: A new ADC is now available to treat the most common subtype of breast cancer / Breast Cancer, cancer, datopotamab deruxtecan, OncoDaily,
oncodaily.com
January 19, 2025 at 4:50 PM
oncodaily.bsky.social
China Approved DATROWAY (Datopotamab Deruxtecan) for HR-Positive, HER2-Negative Metastatic Breast Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DATROWAY #DatopotamabDeruxtecan #BreastCancer #mBC
China Approved DATROWAY (Datopotamab Deruxtecan) for HR-Positive, HER2-Negative Metastatic Breast Cancer - OncoDaily
China approves Datopotamab Deruxtecan (Datroway) for advanced HR-positive, HER2-negative breast cancer after prior therapy.
oncodaily.com
August 26, 2025 at 9:26 PM
onco404.bsky.social
The phase 3 TROPION-Breast01 trial reveals datopotamab deruxtecan (Dato-DXd) 🆚 chemotherapy (ICC) for advanced HR+/HER2− breast cancer:

@ascocancer.bsky.social #jco @breastcancernow.bsky.social

#Onco404 #Cancer #Kanser #BreastCancer #MemeKanseri #ADC #ClinicalTrials #DatopotamabDeruxtecan #MedSky
May 7, 2025 at 5:01 PM
4040rec.bsky.social
#DaiichiSankyo #ADCs #ADClaunches #Enhertu #Datroway #breastcancer #Oncology #antibodydrugconjugates #trastuzumabderuxtecan #datopotamabderuxtecan #pertuzumab #earlystagebreastcancer #triplenegativebreastcancer #Ifinatamabderuxtecan #IDXd #TROPIONBreast05study #ADCtechnology
zurl.co/TySHW
Daiichi Sankyo gears up for five ADC launches in 2026
pharmaphorum.com
March 3, 2026 at 12:32 PM
4040rec.bsky.social
#breastcancer #triplenegativebreastcancer #TNBC #AstraZeneca #AZ #Datroway #datopotamabderuxtecan #DaiichiSankyo #Oncology #TNBCpatients #TROPIONBreast02trial #metastaticTNBC #immunotherapy #TNBCtumours #Gilead #TROP2ADC #Trodelvy #sacituzumabgovitecan #PFSdata
zurl.co/t8A6T
Delayed TNBC readout for Datroway delivers survival benefit
AstraZeneca and Daiichi Sankyo's Datroway comes good in the delayed TROPION-Breast02 trial as a frontline triple-negative breast cancer treatment.
zurl.co
October 7, 2025 at 10:58 AM
medchemexpress.bsky.social
💊#FDAApproval Update | The FDA has approved #Datroway (#datopotamabderuxtecan), the first TROP2-directed antibody-drug conjugate (#ADC) for first-line treatment of unresectable/metastatic triple-negative breast cancer (#TNBC) in patients ineligible for PD-1/PD-L1 therapy
#BreastCancer
May 27, 2026 at 1:01 PM
seldon-dengyue.bsky.social
China aprueba #DatopotamabDeruxtecán (#Datroway)
✔️ HR+ / HER2–
✔️ Enfermedad irresecable o metastásica

📎 Más información: dengyuemed.com/product/dato...
📧 info@dengyuemed.com

#CáncerDeMamaAvanzado #CáncerDeMamaMetastásico #CáncerDeMamaIrresecable #TratamientoDelCáncer #DengYueMedicinasEnHongKong
December 19, 2025 at 8:29 AM
kstrategyand.bsky.social
www.linkedin.com/pulse/fda-ap...

FDA Approves AstraZeneca and Daiichi Sankyo's Datopotamab Deruxtecan: A Breakthrough for Advanced Breast Cancer

kstrategyand.com/pharma-news

#FDAApproval #BreastCancerTreatment #DatopotamabDeruxtecan #MedicalAdvancements #Humanteconomy #Humantec #KStrategyand
FDA Approves AstraZeneca and Daiichi Sankyo's Datopotamab Deruxtecan: A Breakthrough for Advanced Breast Cancer
In a groundbreaking advancement for breast cancer treatment, the FDA has granted approval to datopotamab deruxtecan-dlnk, a Trop-2-directed antibody and topoisomerase inhibitor conjugate. Developed co...
www.linkedin.com
January 23, 2025 at 10:59 AM